America and Britain Announce Duty-Free Accord on Drugs.
Britain and America have signed a major trade agreement that will preserve no import taxes on UK pharmaceutical shipments going into the American market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to boost funding on pharmaceuticals through the NHS. This pledge guarantees that tariffs on these vital exports will be held at zero for a timeframe of the next three years.
This deal follows previous threats to dramatically increase duties on branded pharmaceutical products, with increases mentioned up to one hundred percent.
"This agreement with the United Kingdom reinforces the worldwide climate for innovative medicines and introduces much-needed fairness to U.S.–U.K. pharmaceutical trade," an announcement said.
Trade Importance
Medicines constitute one of the the United Kingdom's largest goods shipped to the US, which is by far the primary destination for large companies like GSK and AstraZeneca.
Trade data show that in the year leading up to the third quarter, the UK exported drugs worth billions to the US. This figure represented a significant portion of total UK exports in that period.
"This agreement safeguards work, boosts capital expenditure and paves the way for the UK to establish itself as a worldwide center for biotech and pharma," a minister stated.
Detailed UK Commitments
The deal involves several notable commitments from the UK:
- Revised Affordability Limit: The UK will raise the affordability limit at which it judges new therapies to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to increase total public funding on drugs from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be limited at fifteen percent. In the past, repayments exceeded 20%.
Industry Background
This agreement comes amid a ongoing dispute between the drug companies and the UK government over spending levels and approval rates.
These tensions were intensified by arguments that US customers were charged significantly more for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several large drug company projects in the UK have been paused or abandoned, while substantial expansions have been directed toward US facilities.
The Science Minister stated that the NHS had to invest a greater share on drugs, noting that its budget allocation on drugs had declined as a share of its overall budget over the previous ten-year period.
